July 2015, Special ASCO Edition
Sharing the Best of ASCO
Each year, we look forward to the American Society of Clinical Oncology (ASCO) Annual Meeting where the oncology community gathers to review the past year and discuss the lessons and successes that will impact the lives of patients. The value in gathering is not only in sharing what we have learned over the past year, but also in renewing our enthusiasm for our chosen profession and enabling us to provide the best in care for our patients.
This year, we are pleased to offer our readers highlights from ASCO in this special edition of Personalized Medicine in Oncology (PMO). It comes as no surprise that the talk of the meeting centered on the progress being made in immunotherapeutic approaches to the treatment of cancers. You will find several feature articles reviewing the topic to include updates in several disease states, biomarkers for immunotherapies, and combination strategies with targeted therapies.
We also turn our attention to a host of other topics, most notably the progress in our understanding of genetics and biomarkers and of lung, prostate, breast, thyroid, kidney, and other cancers. Additionally, the format of this special edition of PMO allows us to expand our focus beyond that of personalized medicine to targeted therapies, biomarkers, and immunotherapies. In this supplement, we explore the topic of value-based care and associated costs. We address this topic in several articles in the hope of providing you a full perspective.
Thank you for your loyal readership. It is our mission to provide you with the most compelling and important information to help you bring the best care to those in need.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
Evidence from a case-control study implicates the number of activating killer-cell immunoglobulin-like receptor (KIR) genes in the risk of developing myelodysplastic syndrome (MDS) as well as being able to distinguish between high-risk and low-risk MDS once the disease is present. Specifically, patients with high-risk MDS had significantly lower numbers of [ Read More ]
In children with favorable-risk Wilms tumor, the presence of a rare genetic abnormality identifies children who can have a survival benefit from the augmentation or intensification of therapy. The abnormality—loss of heterozygosity on chromosomes 1p and 16q (LOH 1p, 16q)—is associated with worse prognosis in children with Wilms tumor. Two [ Read More ]